Last reviewed · How we verify
NCT06801873: 100LPS
Determining the Fingerprint of Endotoxin Tolerance
NA trial testing Endotoxin (E. coli O:113, Reference Endotoxin) in Endotoxemia in 110 participants. Completed in 20 August 2020.
20 February 2020
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 110 |
| Start date | 27 May 2019 |
| Primary completion | 20 February 2020 |
| Estimated completion | 20 August 2020 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Endotoxin (E. coli O:113, Reference Endotoxin) — full drug profile →
Conditions studied
- Endotoxemia — all drugs for Endotoxemia →
- Sepsis — all drugs for Sepsis →
- Systemic Inflammation — all drugs for Systemic Inflammation →
- Immunosuppresion — all drugs for Immunosuppresion →
Sponsor
Radboud University Medical Center
Who can join
Adults 18 to 35, any sex, with Endotoxemia or Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An explorative, prospective study in 100 healthy volunteers who will be challenged with endotoxin twice to identify SNPs and transcripts that are associated with the degree of endotoxin tolerance
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06801873
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endotoxemia
Currently open trials in the same condition.
- NCT05318183 — Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components · NA · active not recruiting
- NCT03901807 — Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study · NA · active not recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06801873 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06801873.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing